Get the Stockscreener App
6.87
8.36%
0.53
Nuvectis Pharma Inc stock is traded at $6.87, with a volume of 70,328.
It is up +8.36% in the last 24 hours and down -14.98% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$6.34
Open:
$6.31
24h Volume:
70,328
Relative Volume:
0.49
Market Cap:
$174.89M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-4.8723
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
+6.84%
1M Performance:
-14.98%
6M Performance:
-9.49%
1Y Performance:
-4.58%
1-Day Range:
$6.31
$6.89
1-Week Range:
$6.11
$6.89
52-Week Range:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.87 | 164.20M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Nuvectis Pharma Inc. stock prediction for this weekShort Setup & Fast Gain Stock Trading Tips - Newser
Nuvectis Pharma Inc. stock chart pattern explained2025 Momentum Check & Fast Gain Stock Tips - Newser
Published on: 2025-08-20 18:42:25 - beatles.ru
Applying Elliott Wave Theory to Nuvectis Pharma Inc.July 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Real time alert setup for Nuvectis Pharma Inc. performanceJuly 2025 Decliners & Free Daily Entry Point Trade Alerts - Newser
How to monitor Nuvectis Pharma Inc. with trend dashboardsProfit Target & Technical Pattern Based Signals - Newser
Can machine learning forecast Nuvectis Pharma Inc. recoveryTake Profit & Growth Focused Stock Pick Reports - Newser
Detecting price anomalies in Nuvectis Pharma Inc. with AI2025 Institutional Moves & Fast Exit Strategy with Risk Control - Newser
Published on: 2025-08-19 22:05:38 - Newser
Key resistance and support levels for Nuvectis Pharma Inc.July 2025 Update & Accurate Intraday Trading Signals - Newser
Published on: 2025-08-19 15:27:43 - Newser
Will Nuvectis Pharma Inc. stock recover after recent drop2025 Trading Volume Trends & Daily Profit Maximizing Tips - Newser
Evaluating Nuvectis Pharma Inc. with trendline analysisTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - Newser
What indicators show strength in Nuvectis Pharma Inc.Weekly Market Outlook & Entry Point Confirmation Signals - Newser
Is Nuvectis Pharma Inc. stock bottoming outJuly 2025 Rallies & Real-Time Volume Spike Alerts - Newser
Candlestick signals on Nuvectis Pharma Inc. stock todayJuly 2025 Review & AI Enhanced Trade Execution Alerts - Newser
Reversal indicators forming on Nuvectis Pharma Inc. stock2025 Institutional Moves & Weekly Watchlist for Consistent Profits - Newser
Does Nuvectis Pharma Inc. fit your quant trading modelPrice Action & Risk Controlled Daily Trade Plans - Newser
Nuvectis Pharma Inc. Inches Toward Key Resistance — Will It BreakMarket Sentiment Review & AI Powered Buy and Sell Recommendations - 선데이타임즈
Nuvectis Pharma Inc. stock daily chart insightsCPI Data & Community Consensus Stock Picks - Newser
Is Nuvectis Pharma Inc. building a consolidation baseQuarterly Trade Summary & Weekly Consistent Profit Watchlists - Newser
What makes Nuvectis Pharma Inc. stock price move sharplyQuarterly Trade Summary & Accurate Intraday Trading Signals - classian.co.kr
Will Nuvectis Pharma Inc. benefit from seasonality2025 Trading Recap & AI Enhanced Trading Alerts - classian.co.kr
Developing predictive dashboards with Nuvectis Pharma Inc. dataQuarterly Risk Review & Low Drawdown Trading Strategies - Newser
Volume spikes in Nuvectis Pharma Inc. stock – what they meanQuarterly Market Summary & Daily Chart Pattern Signal Reports - Newser
Why Nuvectis Pharma Inc. stock attracts strong analyst attentionWeekly Trend Recap & Capital Efficiency Focused Ideas - Newser
Real time scanner hits for Nuvectis Pharma Inc. explainedWeekly Gains Report & Free Fast Gain Swing Trade Alerts - Newser
How to track smart money flows in Nuvectis Pharma Inc.Bond Market & Short-Term Trading Opportunity Alerts - Newser
Is Nuvectis Pharma Inc. trending in predictive chart modelsJuly 2025 Earnings & Trade Opportunity Analysis - Newser
Using R and stats models for Nuvectis Pharma Inc. forecastingTrade Volume Report & Real-Time Buy Zone Alerts - Newser
Exit strategy if you’re trapped in Nuvectis Pharma Inc.Buy Signal & Consistent Return Investment Signals - Newser
Nuvectis Pharma Inc. stock volume spike explainedJuly 2025 Rallies & Long Hold Capital Preservation Plans - Newser
Nuvectis Pharma Q3 EPS Estimate Boosted by HC Wainwright - Defense World
Q3 EPS Estimates for Nuvectis Pharma Lifted by Roth Capital - Defense World
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):